Varian has signed a co-marketing and sales agreement with Embolx to distribute the Sniper Balloon Occlusion Microcatheter in the U.S., expanding its interventional oncology portfolio with a focus on liver-directed therapies.

The partnership enables the Palo Alto, California-based Varian — a Siemens Healthineers company — to offer embolization and ablation solutions from a single vendor. Varian will begin marketing and selling the Sniper device immediately.

The Sniper Balloon Occlusion Microcatheter is designed to improve precision in embolization by using a pressure-directed balloon system to control local blood flow in peripheral vasculature. This targeted approach aims to enhance the delivery of embolic agents to tumor sites while limiting exposure to nearby healthy tissue. The device also supports combination therapy, enabling clinicians to perform embolization followed by ablation during a single intervention.

“Embolization is an important tool for combating treatable disease in growing market segments both within and beyond oncology,” said Dr. David Hahn, chief medical officer for interventional solutions at Varian. “As part of Siemens Healthineers, we are dedicated to improving access to interventional healthcare that can greatly improve both the quality and quantity of life for patients.”

The agreement also includes collaborative efforts in clinician education, training, and support. Both companies plan to promote awareness of the device’s use in image-guided therapies, particularly for intermediate-stage liver metastases, where combining embolization and ablation has shown clinical benefit.

“This co-marketing agreement with Varian is a strategic milestone for Embolx as we expand our impact within the healthcare industry,” said Michael Allen, CEO of Embolx.

Embolx, based in Silicon Valley, develops microcatheters used in embolization procedures targeting tumors, benign prostatic hyperplasia, and uterine fibroids.